The growing need for drug-device combination products results in unique challenges which need to be solved through regulatory systems. The FDA needs companies to demonstrate their ISO 13485 and GMP compliance through the upcoming 2026 implementation of ISO 13485 for Quality Management System Regulation (QMSR 2026). Drug-device combination manufacturers need to understand the relationship between ISO 13485 and GMP standards to sustain their operational efficiency and regulatory compliance.
Choosing a Primary Quality Management System
The very initial requirement of primary QMS within drug-device combos is their selection phase. The company needs to decide between two base systems, which include a device-led ISO 13485 system and a pharma-led GMP system. The choice determines how documents will be controlled and how audits will be scheduled and how work procedures will be executed. The process of aligning ISO 13485 with GMP requirements ensures that essential processes fulfill both device and drug standards, which 21 CFR Part 4 requires for combination products.
Aligning Risk Management: ISO 14971 and ICH Q9
The core element of ISO 13485 and GMP compliance requires organizations to implement risk management procedures. The ISO 14971 standard provides medical device risk management requirements, while the ICH Q9 guideline establishes drug quality risk management procedures. Companies must establish a combined framework for drug-device combinations which meets both QMSR 2026 standards and FDA requirements. The process of risk integration enables organizations to develop safer products while minimizing the need for regulatory inspections.
Post-Market Surveillance and Continuous Improvement
The process of post-market surveillance requires a combined evaluation of both drug and device components in drug-device combination products. ISO 13485 requires monitoring device complaints, while GMP regulations demand monitoring drug deviations. The unified approach of QMSR 2026 enables organizations to meet all FDA requirements which exist in 21 CFR Part 4. The integration of ISO 13485 and GMP standards in surveillance systems enables organizations to implement active quality control measures which support their ongoing development.
Conclusion
The integration process between ISO 13485 and GMP standards for drug-device combination products requires organizations to execute their planning techniques. The selection of a main QMS together with ISO 14971 and ICH Q9 alignment and creation of complete post-market surveillance systems enables companies to achieve compliance with 21 CFR Part 4 and QMSR 2026 requirements.
FAQs
- Do I need two separate Quality Manuals?
No, the unified Quality Manual referring to both requirements of ISO 13485 against GMP and guidance of 21 CFR 4 would be preferred for the drug-device combinations. - Which regulation takes precedence?
According to the previous guidance in 21 CFR 4, the FDA has preeminence. Observing operational impasses, one then has to exercise the balance of considerations between the fundamental principles of ISO 13485 vis-a-vis the principles of GMP within the framework of the proposed enhanced QMSR 2026. - How do I handle Design Control if I am a Pharma-led company?
You need to integrate ISO 13485 design controls into your current GMP processes while achieving compliance with QMSR 2026 regulations and FDA requirements for drug-device combination products.
